Cell

Global Flow Cytometry Market Report 2022: Rise In The Adoption Of The Flow Cytometry Approach In Academia And Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The Global Flow Cytometry Market size is expected to reach $7.7 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period.

Key Points: 
  • The Global Flow Cytometry Market size is expected to reach $7.7 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period.
  • The market for flow cytometry has experienced rapid expansion as a result of the rising prevalence of chronic and infectious disorders.
  • The sample must be a single-cell suspension, which is the most important condition for effective and efficient flow cytometry analysis.
  • One of the elements anticipated to propel the flow cytometry market in the coming years is the rising prevalence of certain disorders.

Cell Culture Protein Surface Coatings Global Market Report 2022: Increased Efficiency and Efficacy Driving Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Cell Culture Protein Surface Coatings Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Culture Protein Surface Coatings Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • The geographic segmentation of the global cell culture protein surface coatings market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global cell culture protein surface coatings market.
  • Furthermore, this report concludes with profiling of key players currently enjoying prominent position in the global cell culture protein surface coatings market.

Medical Radiation Detection, Monitoring & Safety Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 2, 2022

Key Points: 
  • The medical radiation detection, monitoring, and safety market is expected to grow to $2.27 billion in 2026 at a CAGR of 7.9%.
  • The medical radiation detection, monitoring, and safety market consists of sales of medical radiation detection, monitoring, and safety services by entities (organizations, sole traders, and partnerships) that are used for radiation monitoring and detection during medical procedures.
  • Medical radiation detection, monitoring, and safety equipment are designed for detecting and monitoring the intensity of radiation and also protecting the users from the harmful effects of radiation.
  • The medical radiation detection, monitoring, and safety market research report is one of a series of new reports that provides medical radiation detection, monitoring, and safety market statistics, including medical radiation detection, monitoring, and safety industry global market size, regional shares, competitors with medical radiation detection, monitoring, and safety market share, detailed medical radiation detection, monitoring, and safety market segments, market trends and opportunities, and any further data you may need to thrive in the medical radiation detection, monitoring, and safety industry.

EQS-News: First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Retrieved on: 
Friday, December 2, 2022

First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Key Points: 
  • First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM
    The issuer is solely responsible for the content of this announcement.
  • On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra.
  • Enlivexs lead drug candidate, AllocetraTM , was developed as an off-the-shelf cell therapy that reprograms macrophages , the immune cells responsible for killing infected or harmful cells in the body.
  • The next step for this new cell therapy is to test whether these promising preclinical results will translate to human studies.

Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022

Retrieved on: 
Friday, December 2, 2022

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San Diego, CA.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San Diego, CA.
  • The presentation, titled Therapeutic Antibodies to Complex Receptors Exploring the Urokinase Plasminogen Activator Receptor will take place at 2:15 p.m. PST on December 7, 2022.
  • suPAR is well-suited to antibody targeting and we have validated it with human genetics, human therapeutic data, and with animal disease model data.
  • Waldens clinical-stage program is a humanized antibody that inhibits suPAR, a pro-inflammatory mediator that causes podocyte dysfunction and renal disease.

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, December 1, 2022

The stock options were granted as an inducement material to the employees acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as an inducement material to the employees acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price per share equal to $1.33, which represents the closing market price on the Nasdaq Stock Market of TCR2s common stock on the Grant Date.
  • The options are subject to the terms and conditions of TCR2s 2022 Inducement Plan and the stock option agreement covering the grant.
  • This press release contains forward-looking statements, including statements pertaining to the continued service of employees and future vesting of inducement grants.

EQS-News: Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Retrieved on: 
Thursday, December 1, 2022

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Key Points: 
  • Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
    The issuer is solely responsible for the content of this announcement.
  • The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.
  • Then, it can turn that macrophage into a pro-tumor ally that will suppress any immune response trying to kill the cancer.
  • The results of early-stage trials may differ significantly from the results of more developed, later-stage trials.

Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis

Retrieved on: 
Thursday, December 1, 2022

These CTLs will also be studied for the potential use in EBV-related cancers, such as nasopharyngeal carcinoma and certain lymphomas.

Key Points: 
  • These CTLs will also be studied for the potential use in EBV-related cancers, such as nasopharyngeal carcinoma and certain lymphomas.
  • We believe that cell therapies are expected to be the norm, not the exception, said Tevogen CEO Ryan Saadi , M.D., M.P.H.
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.
  • This press release contains certain forward-looking statements relating to Tevogen Bio Inc (the Company) and its business.

AmplifyBio Chooses Blue Mountain to Achieve GMP Compliance and Advance Digital Strategy

Retrieved on: 
Thursday, December 1, 2022

STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.

Key Points: 
  • STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.
  • In one seamlessly integrated system, Blue Mountain RAM provides world-class calibration and maintenance management, all while ensuring GxP compliance.
  • To learn more about AmplifyBio, visit https://www.amplify-bio.com/
    About Blue Mountain Quality Resources:
    Leading the Life Sciences in GMP asset management for 30+ years, Blue Mountain offers deep Life Sciences domain expertise.
  • To learn more about Blue Mountain, visit: https://coolblue.com
    For more information, contact Akashi Perera at 814-234-2417 or [email protected].

Laboratory Animal Diet Global Market Report 2022: Rising Demand for Humanized Mice Models Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The "Laboratory Animal Diet Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diet Type, Animal, Application and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Laboratory Animal Diet Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diet Type, Animal, Application and End User" report has been added to ResearchAndMarkets.com's offering.
  • Rising demand for humanized mice models would provide lucrative opportunities for the market growth during the forecast period.
  • The growing demand for humanized mice models will create an opportunity for the growth of the laboratory animal diet market during the forecast period.
  • Based on diet type, the laboratory animal diet market is segmented into standard diet, irradiated diet, and autoclavable diet.